Titre :

Bevacizumab associated with chemotherapy for initially non-resectable liver metastases from colorectal cancer: a case-control study

Auteur(s) :

Alt, Marie [Auteur]
Truant, Stéphanie [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172

Renaud-Vantroys, Thibaut [Auteur]
Sequier, Cedric [Auteur]
Duhamel, Alain [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
El Amrany, Mehdi [Auteur]
Turpin, Anthony [Auteur]
Makhloufi, Samira [Auteur]
Pruvot, Francois-Rene [Auteur]
Hebbar, Mohamed [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172

Titre de la revue :

Anticancer research

Nom court de la revue :

Anticancer Res.

Numéro :

36

Pagination :

5551-5555

Date de publication :

2016-10-01

ISSN :

0250-7005

Mot(s)-clé(s) en anglais :

Bevacizumab
colorectal cancer
liver metastases

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

The place of bevacizumab in therapy of patients with initially non-resectable liver metastases from colorectal cancer (CRC) remains debated. Bevacizumab may increase the efficacy of chemotherapy but it may also maintain ...
Lire la suite >The place of bevacizumab in therapy of patients with initially non-resectable liver metastases from colorectal cancer (CRC) remains debated. Bevacizumab may increase the efficacy of chemotherapy but it may also maintain dormant micrometastases in a dormant state, eventually increasing the long-term likelihood of tumor relapse. The aim of this study was to explore this hypothesis. A retrospective case-control study was performed in patients with initially non-resectable CRC liver metastases. Metastases were rendered resectable after chemotherapy with (cases) or without (controls) bevacizumab. Cases and controls were matched for synchronicity, number and maximal size of metastases. The main objective was the disease-free survival (DFS). A total of 82 patients were enrolled (41 in each group). The median DFS was 12.0 months in the bevacizumab group, and 10.2 months in the group treated with chemotherapy alone (p=0.26). We observed no significant effect on DFS for bevacizumab when added to chemotherapy in patients with initially non-resectable liver metastases. Prospective trials on this issue are warranted.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172
• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2019-12-09T18:15:35Z